119 related articles for article (PubMed ID: 7631520)
1. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability.
Lipford GB; Bauer S; Wagner H; Heeg K
Vaccine; 1995 Feb; 13(3):313-20. PubMed ID: 7631520
[TBL] [Abstract][Full Text] [Related]
2. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
Lipford GB; Hoffman M; Wagner H; Heeg K
J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
[TBL] [Abstract][Full Text] [Related]
3. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
4. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant.
Nikolić-Zugić J; Carbone FR
Eur J Immunol; 1990 Nov; 20(11):2431-7. PubMed ID: 2253683
[TBL] [Abstract][Full Text] [Related]
5. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
[TBL] [Abstract][Full Text] [Related]
6. Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs.
Jameson SC; Bevan MJ
Eur J Immunol; 1992 Oct; 22(10):2663-7. PubMed ID: 1396971
[TBL] [Abstract][Full Text] [Related]
7. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues.
Chen W; Khilko S; Fecondo J; Margulies DH; McCluskey J
J Exp Med; 1994 Oct; 180(4):1471-83. PubMed ID: 7523572
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis.
Fonseca DP; Joosten D; Snippe H; Verheul AF
Mol Immunol; 2000 Jun; 37(8):413-22. PubMed ID: 11090876
[TBL] [Abstract][Full Text] [Related]
9. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
[TBL] [Abstract][Full Text] [Related]
10. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
Lipford GB; Bauer S; Wagner H; Heeg K
Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
[TBL] [Abstract][Full Text] [Related]
11. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product.
Guimezanes A; Schumacher TN; Ploegh HL; Schmitt-Verhulst AM
Eur J Immunol; 1992 Jun; 22(6):1651-4. PubMed ID: 1318201
[TBL] [Abstract][Full Text] [Related]
12. Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?
Calin-Laurens V; Trescol-Biémont MC; Gerlier D; Rabourdin-Combe C
Vaccine; 1993; 11(9):974-8. PubMed ID: 7692684
[TBL] [Abstract][Full Text] [Related]
13. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.
Carbone FR; Bevan MJ
J Exp Med; 1989 Mar; 169(3):603-12. PubMed ID: 2784478
[TBL] [Abstract][Full Text] [Related]
14. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production.
Chen SS; Gong J; Yang YM; Oettgen H; Zanetti M
Cell Immunol; 2005 Jan; 233(1):11-22. PubMed ID: 15913585
[TBL] [Abstract][Full Text] [Related]
16. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
17. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
Ma H; Kapp JA
Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
[TBL] [Abstract][Full Text] [Related]
18. A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway.
Pietersz GA; Li W; Apostolopoulos V
Vaccine; 2001 Jan; 19(11-12):1397-405. PubMed ID: 11163662
[TBL] [Abstract][Full Text] [Related]
19. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
[TBL] [Abstract][Full Text] [Related]
20. Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness.
Wettstein PJ; van Bleek GM; Nathenson SG
J Immunol; 1993 Apr; 150(7):2753-60. PubMed ID: 7681080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
